Expression of Bcl‐2 Family Proteins in Advanced Laryngeal Squamous Cell Carcinoma: Correlation With Response to Chemotherapy and Organ Preservation
- 1 April 2002
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 112 (4), 638-644
- https://doi.org/10.1097/00005537-200204000-00009
Abstract
Objectives/Hypothesis Induction chemotherapy and definitive radiation therapy in advanced laryngeal cancer has been shown to achieve survival rates that are similar to total laryngectomy and postoperative radiation therapy. In patients with advanced laryngeal cancer, quality of life can be significantly enhanced by treatment regimens that preserve the larynx. However, which patients will respond best to organ preservation protocols remains unknown. The Bcl-2 family proteins are involved in control of apoptosis and, potentially, tumor response to chemotherapy. Study Design Retrospective analysis of immunohistochemical tumor characteristics and clinical outcome. Methods To determine whether Bcl-2 family proteins were predictive of successful organ preservation, immunohistochemical analysis of tissue specimens from 47 patients with advanced laryngeal cancer from the U.S. Department of Veterans Affairs Cooperative Study Program (VA CSP-268) were evaluated for the expression of Bcl-2, Bcl-XL, and Bax protein expression. Tumor response was classified as either complete or partial/nonresponse after induction chemotherapy. Protein expression was correlated with tumor response, organ preservation, and overall patient survival. Results The Bcl-2 protein was expressed at high levels in only 15% of specimens, but five of seven tumors with high Bcl-2 showed complete response (P = .10). The majority of tumors expressed high levels of Bcl-XL (74%). Reduced expression of Bcl-XL was associated with a complete response (P = .143) and with larynx preservation (P =.06). Most patients (81%) had increased levels of Bax expression. Reduced expression of Bax was associated with a complete response rate (P = .074), but there was no correlation between Bax expression and larynx preservation. Conclusions The findings indicate that laryngeal cancer cells typically produce high levels of only one of the apoptosis protective proteins, Bcl-2 or Bcl-XL. Prospective studies of larger numbers of patients are under way to determine whether Bcl-XL expression will be a useful marker predicting larynx preservation.Keywords
This publication has 25 references indexed in Scilit:
- Bcl-xLIs Expressed in Ovarian Carcinoma and Modulates Chemotherapy-Induced ApoptosisGynecologic Oncology, 1998
- Regulators of Proliferation and Apoptosis in Carcinoma of the LarynxThe Laryngoscope, 1998
- Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice.Journal of Clinical Investigation, 1996
- Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistanceCurrent Opinion in Oncology, 1995
- The Bcl-2 Protein: a Prognostic Indicator Strongly Related to p53 Protein in Lymph Node-Negative Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- bcl-2 Protein in Non-Small-Cell Lung CarcinomaNew England Journal of Medicine, 1993
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell deathCell, 1993
- Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal CancerNew England Journal of Medicine, 1991
- Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cellsNature, 1988